Androgen Deprivation Therapy for Prostate Cancer Influences Body Composition Increasing Risk of Sarcopenia
Nutrients · 28.03.2023 · 15 (7) · 1631
DOI: 10.3390/nu15071631 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, online erschienen am 28.03.2023. Verfasst von Jolanta Korczak und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemotherapy, The Greater Poland Cancer Center, 61-866 Poznan, Poland. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Sarcopenia. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Computed tomography (CT) scans used in treatment response assessment in prostate cancer (PCa) patients are a useful tool for nutritional status evaluation. The aim of this study was to assess the nutritional status, including sarcopenia development based on CT scans, in PCa patients and its association with progression-free survival (PFS). Sixty-four PCa patients were included (group 1: 34 patients undergoing androgen deprivation therapy (ADT) with docetaxel due to newly diagnosed, hormone-sensitive, metastatic PCa and group 2: 30 patients with castration-resistant metastatic PCa continuing ADT therapy with enzalutamide or abiraterone acetate). Nutritional status was evaluated with anthropometrical parameters, Nutritional Risk Score (NRS), and CT scans at the L3 vertebrae. Survival analyses were performed. According to NRS, nutritional status was significantly related to PFS. In both groups, there was a significant reduction in muscle tissue (total muscle tissue and skeletal muscle index). A significant increase in the distribution of adipose tissue (subcutaneous fat, visceral fat, subcutaneous adipose tissue index, and visceral adipose tissue index) in group one was observed. Sarcopenia was diagnosed in patients but with no influence on PFS. Significant reduction in muscle mass and increase in fat mass was observed in patients treated for PCa with no impact on PFS. The NRS was related to PFS in PCa patients and associated with body composition, assessed by CT after the castration therapy. Long-term castration combined with abiraterone therapy with prednisone or enzalutamide significantly influenced muscle tissue and may lead to sarcopenia development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemotherapy, The Greater Poland Cancer Center, 61-866 Poznan, Poland.
- Department of Gynecological Oncology, Institute of Oncology, Poznan University of Medical Sciences, 61-569 Poznan, Poland.
- Department of Cancer Pathology and Prevention, Poznan University of Medical Sciences, 61-866 Poznan, Poland.
- Department of Obesity Treatment, Metabolic Disorders and Clinical Dietetics, Poznan University of Medical Sciences, 61-569 Poznan, Poland.
ORCID-Profile: Paweł Bogdański, Marta Stelmach-Mardas
Zitieren
APA
Korczak, J., Mardas, M., Litwiniuk, M., Bogdański, P., & Stelmach-Mardas, M. (2023). Androgen Deprivation Therapy for Prostate Cancer Influences Body Composition Increasing Risk of Sarcopenia. Nutrients, 15(7), 1631. https://doi.org/10.3390/nu15071631
Vancouver
Korczak J, Mardas M, Litwiniuk M, Bogdański P, Stelmach-Mardas M. Androgen Deprivation Therapy for Prostate Cancer Influences Body Composition Increasing Risk of Sarcopenia. Nutrients. 2023;15(7):1631. doi:10.3390/nu15071631
BibTeX
@article{Korczak2023,
author = {Korczak, Jolanta and Mardas, Marcin and Litwiniuk, Maria and Bogdański, Paweł and Stelmach-Mardas, Marta},
title = {Androgen Deprivation Therapy for Prostate Cancer Influences Body Composition Increasing Risk of Sarcopenia},
journal = {Nutrients},
year = {2023},
volume = {15},
number = {7},
pages = {1631},
doi = {10.3390/nu15071631}
}
EUVIMED